Bayer's Menopause Relief Medication Receives Approval from US FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Source: Reuters
FDA Approval: The U.S. FDA has approved Bayer's non-hormonal drug Lynkuet for easing hot flashes in menopausal women, following a three-month review extension.
Availability and Cost: Lynkuet will be available in the U.S. starting November at a wholesale cost of $625 per month, with potential discounts for eligible patients through a partnership with BlinkRx.
Clinical Studies: The approval was based on three late-stage studies demonstrating the drug's effectiveness in reducing the frequency and severity of hot flashes and improving sleep disturbances.
Warnings and Other Treatments: Lynkuet carries warnings about possible side effects, and it is one of two approved non-hormonal treatments for hot flashes in the U.S., alongside Astellas' Veozah.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
